Thermo Fisher Scientific has announced a major strategic divestment, agreeing to sell its microbiology business to European private equity firm Astorg for approximately $1.075 billion (around ₹9,000+ crore).
The microbiology unit plays a critical role in global diagnostics, providing products such as antimicrobial susceptibility testing systems and culture media used across clinical, pharmaceutical, and food safety applications. The business generated around $645 million in revenue in 2025 and operates through a global network of manufacturing and R&D facilities.
The transaction, which includes both cash and a $50 million seller note, is expected to close in the second half of 2026, subject to regulatory approvals. Until then, Thermo Fisher will continue to operate the unit as usual.
This move reflects Thermo Fisher’s broader strategy to actively manage its portfolio and focus on higher growth segments within life sciences and specialty diagnostics. The company has been reshaping its business through both acquisitions and divestitures, including its recent multi billion dollar deal for clinical research firm Clario.
For Astorg, the acquisition aligns with its continued focus on healthcare and life sciences investments. The firm, which manages over $28 billion in assets, is known for acquiring and scaling specialized healthcare businesses globally.
Industry experts view the deal as part of a broader trend where large healthcare companies streamline operations while private equity firms capitalize on carve outs to drive innovation and growth in niche segments.
“The transaction reflects our active management of the company and provides additional capital we can deploy to create shareholder value.”
By
HB Team
